AI Article Synopsis
- Epilepsy affects over 60 million people globally, with intractable epilepsy (IE) occurring in 20%-30% of patients who cannot control seizures with medication.
- The review suggests that multidrug transporters, particularly P-glycoprotein (P-gp), may hinder the effectiveness of antiepileptic drugs (AEDs) by facilitating drug efflux at the blood-brain barrier.
- The authors provide evidence from various sources, including animal studies, pharmacological research, clinical cases, and genetic studies, to support the idea that P-gp overexpression is linked to intractable epilepsy.
Article Abstract
Epilepsy is a serious neurological disorder that affects more than 60 million people worldwide. Intractable epilepsy (IE) refers to approximately 20%-30% of epileptic patients who fail to achieve seizure control with antiepileptic drug (AED) treatment. Although the mechanisms underlying IE are not well understood, it has been hypothesized that multidrug transporters such as P-glycoprotein (P-gp) play a major role in drug efflux at the blood-brain barrier, and may be the underlying factor in the variable responses of patients to AEDs. The main goal of the present review is to show evidence from different areas that support the idea that the overexpression of P-gp is associated with IE. We discuss here evidence from animal studies, pharmacology, clinical cases and genetic studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00207454.2015.1038710 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!